Retroperitoneal lymph node dissection after chemotherapy

BJU International

Volumn 104, Issue 9 B, 2009, Pages 1404-1412

  Winter, Christian ^a   Raman, Jay D ^b   Sheinfeld, Joel ^c   Albers, Peter ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; TUMOR MARKER; VINBLASTINE;

CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; EJACULATION; FERTILITY; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; NECROSIS; ORCHIECTOMY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TERATOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; EJACULATION; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; ORCHIECTOMY; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RETROPERITONEAL NEOPLASMS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TERATOMA; TESTICULAR NEOPLASMS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 70350441765     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08867.x     Document Type: Review

References (120)

1. Sheinfeld J, Bajorin D, Solomon M. Management of postchemotherapy residual masses in advanced germ cell tumors. AUA Update Ser 1997 17 : 18 24
2. Bajorin DF, Herr H, Motzer RJ, Bosl GJ. Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors. Semin Oncol 1992 19 : 148 158
3. Sheinfeld J. The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies. Semin Urol Oncol 2002 20 : 262 271
4. Merrin C, Takita H, Beckley S, Kassis J. Treatment of recurrent and widespread testicular tumor by radical reductive surgery and multiple sequential chemotherapy. J Urol 1977 117 : 291 295
5. Donohue JP, Einhorn LH, Williams SD. Cytoreductive surgery for metastatic testis cancer: considerations of timing and extent. J Urol 1980 123 : 876 880
6. Bosl G, Bajorin D, Sheinfeld J. Cancer of the testis. In De Vita VT Jr., Hellman S, Rosenberg SA eds, Cancer: Principles and Practice of Oncology. Philadelphia : Lippincott Williams & Wilkins, 2005 : 1269 1290
7. Donohue JP, Roth LM, Zachary JM et al. Cytoreductive surgery for metastatic testis cancer: tissue analysis of retroperitoneal masses after chemotherapy. J Urol 1982 127 : 1111 1114
8. Einhorn LH. Testicular cancer as a model for a curable neoplasm. The Richard Hinda Rosenthal Foundation Award Lecture. Cancer Res 1981 41 : 3275 80
9. Donohue JP, Rowland RG. The role of surgery in advanced testicular cancer. Cancer 1984 54 (Suppl. 2716 2721
10. Bosl GJ, Gluckman R, Geller NL et al. VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors. J Clin Oncol 1986 4 : 1493 1499
11. Bosl GJ, Geller NL, Bajorin D et al. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 1988 6 : 1231 1238
12. Einhorn LH, Williams SD, Loehrer PJ et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989 7 : 387 391
13. Einhorn LH, Williams SD, Troner M et al. The role of maintenance therapy in disseminated testicular cancer. N Engl J Med 1981 305 : 727 731
14. Peckham MJ. Surveillance following orchiectomy for clinical stage I testicular germ-cell malignancy. Prog Clin Biol Res 1985 203 : 523 538
15. Fossa SD, Ous S, Lien HH, Stenwig AE. Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol 1989 141 : 557 559
16. Levitt MD, Reynolds PM, Sheiner HJ et al. Non-seminomatous germ cell testicular tumours: residual masses after chemotherapy. Br J Surg 1985 72 : 19 22
17. Carter GE, Lieskovsky G, Skinner DG, Daniels JR. Reassessment of the role of adjunctive surgical therapy in the treatment of advanced germ cell tumors. J Urol 1987 138 : 1397 1401
18. Donohue JP, Rowland RG, Kopecky K et al. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol 1987 137 : 1176 1179
19. Gelderman WA, Schraffordt Koops H, Sleijfer DT et al. Results of adjuvant surgery in patients with stage III and IV nonseminomatous testicular tumors after cisplatin-vinblastine-bleomycin chemotherapy. J Surg Oncol 1988 38 : 227 232
20. Stomper PC, Jochelson MS, Garnick MB, Richie JP. Residual abdominal masses after chemotherapy for nonseminomatous testicular cancer: correlation of CT and histology. AJR Am J Roentgenol 1985 145 : 743 746
21. Levi JA, Thomson D, Sandeman T et al. A prospective study of cisplatin-based combination chemotherapy in advanced germ cell malignancy: role of maintenance and long-term follow-up. J Clin Oncol 1988 6 : 1154 1160
22. Wozniak AJ, Samson MK Shah NT et al. A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study. J Clin Oncol 1991 9 : 70 6
23. Ozols RF, Ihde DC, Linehan WM et al. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 1988 6 : 1031 1040
24. Williams SD, Birch R, Einhorn LH et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987 316 : 1435 1440
25. Fossa SD, Qvist H, Stenwig AE et al. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol 1992 10 : 569 573
26. Tait D, Peckham MJ, Hendry WF, Goldstraw P. Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma. Br J Cancer 1984 50 : 601 609
27. Freiha FS Shortliffe LD Rouse RV et al. The extent of surgery after chemotherapy for advanced germ cell tumors. J Urol 1984 132 : 915 917
28. Steyerberg EW, Keizer HJ, Fossa SD et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 1995 13 : 1177 1187
29. Steyerberg EW, Vergouwe Y, Keizer HJ, Habbema JD. Residual mass histology in testicular cancer: development and validation of a clinical prediction rule. Stat Med 2001 20 : 3847 3859
30. Stenning SP, Parkinson MC, Fisher C et al. Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer 1998 83 : 1409 1419
31. Steiner H, Peschel R, Bartsch G. Retroperitoneal lymph node dissection after chemotherapy for germ cell tumours: is a full bilateral template always necessary? BJU Int 2008 102 : 310 314
32. Heidenreich A, Pfister D, Witthuhn R, Thüer D, Albers P. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol 2008 53 : 260 272
33. Beck SD, Foster RS, Bihrle R, Donohue JP, Einhorn LH. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? Cancer 2007 110 : 1235 1240
34. Spiess PE, Brown GA, Pisters LL et al. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? Cancer 2006 107 : 1503 1510
35. Sheinfeld J, McKernian J, Bosl GJ. Surgery of testicular tumors. In Walsh PC, Retik AB eds, Vaughan ED et al., Campbell's Urology, 8th edn. Philadelphia : WB Saunders, 2002 : 2920 2944
36. Fox EP, Weathers TD, Williams SD et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 1993 11 : 1294 1299
37. Eggener SE, Carver BS, Loeb S et al. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer 2007 109 : 528 535
38. Richie JP, Garnick MB, Finberg H. Computerized tomography: how accurate for abdominal staging of testis tumors? J Urol 1982 127 : 715 717
39. Mead GM, Stenning SP, Parkinson MC et al. The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol 1992 10 : 85 94
40. Oldenburg J, Alfsen GC, Lien HH et al. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 2003 21 : 3310 3317
41. Richie JP. The surgical management of advanced abdominal disease. Semin Urol 1984 2 : 238 243
42. Toner GC, Panicek DM, Heelan RT et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 1990 8 : 1683 1694
43. Husband JE, Hawkes DJ, Peckham MJ. CT estimations of mean attenuation values and volume in testicular tumors: a comparison with surgical and histologic findings. Radiology 1982 144 : 553 558
44. Beck SD, Foster RS, Bihrle R et al. Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer. J Urol 2002 168 : 1402 1404
45. Carver BS, Bianco FJ Jr., Shayegan B et al. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection. J Urol 2006 176 : 100 103
46. Debono DJ, Heilman DK, Einhorn LH et al. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol 1997 15 : 1455 1464
47. Loehrer PJ Sr., Hui S, Clark S et al. Teratoma following cisplatin-based combination chemotherapy for nonseminomatous germ cell tumors: a clinicopathological correlation. J Urol 1986 135 : 1183 1189
48. Lassen U, Daugaard G, Eigtved A et al. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging 2003 30 : 396 402
49. Cremerius U, Wildberger JE, Borchers H et al. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? - Results of a study in 50 patients. Urology 1999 54 : 900 4
50. Albers P, Bender H, Yilmaz H et al. Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. Urology 1999 53 : 808 811 (Pubitemid 29163051)
51. Spermon JR, De Geus-Oei LF, Kiemeney LA et al. The role of (18) fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int 2002 89 : 549 556
52. Bouchelouche K, Oehr P. Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review. J Urol 2008 179 : 34 45
53. De Santis M, Becherer A, Bokemeyer C et al. 2-18fluoro-deoxy-d-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004 22 : 1034 1039
54. Oechsle K, Hartmann M, Brenner W et al. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol 2008 26 : 5930 5935
55. Huddart RA, O'Doherty MJ, Padhani A et al. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22 - the NCRI Testis Tumour Clinical Study Group. J Clin Oncol 2007 25 : 3090 3095
56. de Wit M, Brenner W, Hartmann M et al. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol 2008 19 : 1619 1623
57. Fossa SD, Aass N, Ous S et al. Histology of tumor residuals following chemotherapy in patients with advanced nonseminomatous testicular cancer. J Urol 1989 142 : 1239 1242
58. Steyerberg EW, Gerl A, Fossa SD et al. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J Clin Oncol 1998 16 : 269 274
59. Vergouwe Y, Steyerberg EW, Foster RS et al. Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicentre validation with more than 1000 patients. Eur Urol 2007 51 : 424 432
60. Albers P, Weissbach L, Krege S et al. Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol 2004 171 : 1835 1838
61. Motzer RJ, Bajorin DF, Vlamis V et al. Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience. Semin Oncol 1992 19 (Suppl. 12 8 11
62. Hendry WF, Norman AR, Dearnaley DP et al. Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer 2002 94 : 1668 1676
63. Hendry WF, A'Hern RP, Hetherington JW et al. Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: prognostic value and therapeutic benefit. Br J Urol 1993 71 : 208 213
64. Wood DP Jr., Herr HW, Heller G et al. Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol 1992 148 : 1812 5
65. Eggener SE, Carver BS, Sharp DS et al. The incidence and implications of disease outside a modified template in men undergoing post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for metastatic non-seminomatous germ cell tumors (NSGCT). J Urol 2006 175 : 192
66. Coogan CL, Hejase MJ, Wahle GR et al. Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. J Urol 1996 156 : 1656 1658
67. Wahle GR, Foster RS, Bihrle R et al. Nerve sparing retroperitoneal lymphadenectomy after primary chemotherapy for metastatic testicular carcinoma. J Urol 1994 152 : 428 430
68. Pettus JA, Carver BS, Masterson T, Stasi J, Sheinfeld J. Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer. Urology 2009 73 : 328 331
69. Donohue JP, Foster RS. Retroperitoneal lymphadenectomy in staging and treatment. The development of nerve-sparing techniques. Urol Clin North Am 1998 25 : 461 468
70. Donohue JP. Retroperitoneal lymphadenectomy in staging and treatment of clinical stage I and II nonseminomatous testis cancer (NSGCT): the development of nerve-sparing techniques. Cancer Treat Res 1996 88 : 105 119
71. Beck SD, Foster RS, Bihrle R et al. Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection. J Urol 2001 165 : 1517 1520
72. Kelly R, Skinner D, Yellin AE, Weaver FA. En bloc aortic resection for bulky metastatic germ cell tumors. J Urol 1995 153 : 1849 1851
73. Nash PA, Leibovitch I, Foster RS et al. En bloc nephrectomy in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous testis cancer: indications, implications and outcomes. J Urol 1998 159 : 707 710
74. Stephenson AJ, Tal R, Sheinfeld J. Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. J Urol 2006 176 : 1996 1999
75. Neyer M, Peschel R, Akkad T et al. Long-term results of laparoscopic retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testicular cancer. J Endourol 2007 21 : 180 183
76. Abdel-Aziz KF, Anderson JK, Svatek R et al. Laparoscopic and open retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testis tumors. J Endourol 2006 20 : 627 631
77. Rassweiler JJ, Scheitlin W, Heidenreich A et al. Laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumors: indications and limitations. J Urol 1996 156 : 1108 1113
78. Rassweiler JJ, Henkel TO, Stock C et al. Retroperitoneal laparoscopic lymph node dissection for staging non-seminomatous germ cell tumors before and after chemotherapy. Lymphology 1996 29 : 36 44
79. Palese MA, Su LM, Kavoussi LR. Laparoscopic retroperitoneal lymph node dissection after chemotherapy. Urology 2002 60 : 130 134
80. Albers P. Surgery in testis cancer: laparoscopic and open techniques. Curr Opin Urol 2002 12 : 435 440
81. Permpongkosol S, Lima GC, Warlick CA et al. Postchemotherapy laparoscopic retroperitoneal lymph node dissection: evaluation of complications. Urology 2007 69 : 361 365
82. Albqami N, Janetschek G. Laparoscopic retroperitoneal lymph-node dissection in the management of clinical stage I and II testicular cancer. J Endourol 2005 19 : 683 692 discussion 692
83. Corvin S, Kuczyk M, Anastasiadis A et al. Laparoscopic retroperitoneal lymph node dissection for nonseminomatous testicular carcinoma. World J Urol 2004 22 : 33 6
84. Correa JJ, Politis C, Rodriguez AR, Pow-Sang JM. Laparoscopic retroperitoneal lymph node dissection in the management of testis cancer. Cancer Control 2007 14 : 258 264
85. Bhayani SB, Ong A, Oh WK, Kantoff PW, Kavoussi LR. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update. Urology 2003 62 : 324 327
86. Corvin S, Sturm W, Kuczyk M, Anastasiadis AG, Stenzl A. Laparoscopic retroperitoneal lymphadenectomy in the management of low-stage testicular cancer: technique and results. Minim Invasive Ther Allied Technol 2005 14 : 52 6
87. Corvin S, Sturm W, Schlatter E, Anastasiadis A, Kuczyk M, Stenzl A. Laparoscopic retroperitoneal lymph-node dissection with the waterjet is technically feasible and safe in testis-cancer patient. J Endourol 2005 19 : 823 826
88. Cresswell J, Scheitlin W, Gozen A, Lenz E, Teber D, Rassweiler JJ. Laparoscopic retroperitoneal lymph node dissection combined with adjuvant chemotherapy for pathological stage II disease in nonseminomatous germ cell tumours: a 15-year experience. BJU Int 2008 102 : 844 848
89. Rassweiler JJ, Scheitlin W, Heidenreich A, Laguna MP, Janetschek G. Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective. Eur Urol 2008 54 : 1004 1015
90. Donohue JP, Leviovitch I, Foster RS, Baniel J, Tognoni P. Integration of surgery and systemic therapy: results and principles of integration. Semin Urol Oncol 1998 16 : 65 71
91. Einhorn LH, Williams SD, Mandelbaum I, Donohue JP. Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. Cancer 1981 48 : 904 908
92. Geller NL, Bosl GJ, Chan EY. Prognostic factors for relapse after complete response in patients with metastatic germ cell tumors. Cancer 1989 63 : 440 445
93. Logothetis CJ, Samuels ML. Surgery in the management of stage III germinal cell tumors. Observations on the M.D. Anderson Hospital experience 1971-79. Cancer Treat Rev 1984 11 : 27 37
94. Fizazi K, Tjulandin S, Salvioni R et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy - results from an international study group. J Clin Oncol 2001 19 : 2647 2657
95. Logothetis CJ, Samuels ML Trindade A Johnson DE. The growing teratoma syndrome. Cancer 1982 50 : 1629 1635
96. Morgentaler A Garnick MB Richie JP. Metastatic testicular teratoma invading the inferior vena cava. J Urol 1988 140 : 149 150
97. Motzer RJ Amsterdam A, Prieto V et al. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol 1998 159 : 133 138
98. Ahmed T, Bosl GJ, Hajdu SI. Teratoma with malignant transformation in germ cell tumors in men. Cancer 1985 56 : 860 863
99. Ulbright TM, Loehrer PJ, Roth LM et al. The development of non-germ cell malignancies within germ cell tumors. A clinicopathologic study of 11 cases. Cancer 1984 54 : 1824 1833
100. Spiess PE, Pisters LL, Liu P et al. Malignant transformation of testicular teratoma: a chemoresistant phenotype. Urol Oncol 2008 26 : 595 599
101. Donadio AC, Motzer RJ, Bajorin DF et al. Chemotherapy for teratoma with malignant transformation. J Clin Oncol 2003 21 : 4285 4291
102. Dieckmann KP, Albers P, Classen J et al. Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J Urol 2005 173 : 824 829
103. Borge N, Fossa SD, Ous S et al. Late recurrence of testicular cancer. J Clin Oncol 1988 6 : 1248 1253
104. Gerl A, Clemm C, Schmeller N et al. Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 1997 8 : 41 7
105. Ehrlich Y, Baniel J. Late relapse of testis cancer. Urol Clin North Am 2007 34 : 253 258 abstract x xi
106. George DW, Foster RS, Hromas RA et al. Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol 2003 21 : 113 122
107. Rick O, Bokemeyer C, Weinknecht S et al. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. J Clin Oncol 2004 22 : 3713 3719
108. Wood DP Jr., Herr HW, Motzer RJ et al. Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. Cancer 1992 70 : 2354 2357
109. Murphy BR, Breeden ES, Donohue JP et al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 1993 11 : 324 329
110. Eastham JA, Wilson TG, Russell C et al. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. Urology 1994 43 : 74 80
111. Albers P, Ganz A, Hannig E et al. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol 2000 164 : 381 384
112. Sheinfeld J, Sogani P. Re-operative retroperitoneal surgery in testicular cancer. Urol Clinics North Am 2007 34 : 227 233
113. Sexton WJ, Wood CG, Kim R et al. Repeat retroperitoneal lymph node dissection for metastatic testis cancer. J Urol 2003 169 : 1353 1356
114. McKiernan JM, Motzer RJ, Bajorin DF et al. Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. Urology 2003 62 : 732 736
115. Baniel J, Sella A. Complications of retroperitoneal lymph node dissection in testicular cancer: primary and post-chemotherapy. Semin Surg Oncol 1999 17 : 263 267
116. Mosharafa AA, Foster RS, Koch MO, Bihrle R, Donohue JP. Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. J Urol 2004 171 : 1839 1841
117. Donat SM, Levy DA. Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary? J Urol 1998 160 : 1347 1352
118. Chang SS, Mohseni HF, Leon A, Sheinfeld J. Paracolic recurrence: the importance of wide excision of the spermatic cord at retroperitoneal lymph node dissection. J Urol 2002 167 : 94 6
119. Jacobsen KD, Ous S, Waehre H et al. Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection. Br J Cancer 1999 80 : 249 255
120. Albers P. Resection of retroperitoneal residual tumor after chemotherapy for testicular cancer indication and surgical techniques. Crit Rev Oncol Hematol 2004 50 : 79 85